I started with CNET reviewing laptops in 2009. Now I explore wearable tech, VR/AR, tablets, gaming and future/emerging trends in our changing world. Other obsessions include magic, immersive theater, ...
Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s ...
Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker. CagriSema is a ...
Jess Loren remembers loving the taste of Cap'n Crunch cereal. Coca-Cola. Snickers bars. But now, instead of a sweetness, "they taste bland," she says. Flavors are noticeably muted since she started a ...
DEC 15 (Reuters) - A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while ...
GLP-1 usage is on the rise, and researchers are looking for other health benefits associated with the drug, including its effects on bladder health. But as GLP-1s rise in popularity, so do nicknames ...
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also ...
SALT LAKE CITY — Weight-loss drugs have surged in popularity in recent years, with as many as 12% of Americans having tried a glucagon-like peptide-1 (GLP-1) medication such as Ozempic, Wegovy, ...
Now, GLP-1s are available for weight loss, but plenty of misconceptions exist about how best to use these drugs. It may sound nice to think about taking GLP-1s and watching the numbers on your scale ...
The World Health Organization conditionally recommends the use of GLP-1 drugs, including tirzepatide, marketed as Mounjaro and Zepbound, for obesity treatment. Peter Dazeley via Getty Images The World ...
XREAL is wrapping up 2025 with the launch of a new entry-level AR glasses model, the XREAL 1S. It sits below the more expensive XREAL One Pro (announced in July) in the lineup and is the first in the ...
Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results